The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | DLIx as a prognostic tool for LBCL patients receiving axi-cel
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study aiming to evaluate the significance of patient delta lymphocyte index (DLIx) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel). A complete response (CR) was achieved in 54% of patients. Patients achieving a CR exhibited higher DLIx values and low DLIx was associated with significantly shorter median progression-free survival (PFS) and overall survival (OS). These findings indicate that DLIx has a prognostic value in patients with R/R LBCL treated with axi-cel. Further studies evaluating how different factors impact DLIx may lead to optimization of conditioning therapy, thus improving CAR T-cell therapy efficacy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
